Online inquiry

IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4759MR)

This product GTTS-WQ4759MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets SOST gene. The antibody can be applied in Osteogenesis imperfecta (OI) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_025237.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50964
UniProt ID Q9BQB4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ4759MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13339MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ1517MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACE-011
GTTS-WQ6209MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ3701MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ2057MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ15418MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA TSR-022
GTTS-WQ11615MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MGD-006
GTTS-WQ5507MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP4940
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW